Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: results from NAVIGATOR.

Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: results from NAVIGATOR.

Εμφάνιση άλλων εκδόσεων (1)

OBJECTIVE: The cardiometabolic risk cluster metabolic syndrome (MS) includes ≥3 of elevated fasting glucose, hypertension, elevated triglycerides, reduced high-density lipoprotein cholesterol (HDL-c), and increased waist circumference. Each can be affected by physical activity and diet. Our objectiv...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Huffman, K, Sun, J, Thomas, L, Bales, C, Califf, R, Yates, T, Davies, M, Holman, R, McMurray, J, Bethel, M, Tuomilehto, J, Haffner, S, Kraus, W
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	2014

Παρόμοια τεκμήρια

Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: Results from NAVIGATOR
ανά: Huffman, K, κ.ά.
Έκδοση: (2014)

Association of Baseline Physical Activity by Pedometer Counts and Nutritional Behavior on Metabolic Syndrome in the NAVIGATOR Study
ανά: Huffman, K, κ.ά.
Έκδοση: (2013)

Relations between Baseline Physical Activity by Pedometer Counts and Future Cardiovascular Events in the NAVIGATOR Study
ανά: Kraus, W, κ.ά.
Έκδοση: (2012)

Association of non-alcoholic steatothepatitis with components of the metabolic syndrome in 43,509 patients screened for NAVIGATOR
ανά: Bethel, A, κ.ά.
Έκδοση: (2005)

Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis.
ανά: Yates, T, κ.ά.
Έκδοση: (2014)

Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): A cohort analysis
ανά: Yates, T, κ.ά.
Έκδοση: (2014)

Diet and other health-related behaviors of individuals with impaired glucose tolerance, cardiovascular disease (CVD) or CVD risk: A global view from the NAVIGATOR study
ανά: Bales, C, κ.ά.
Έκδοση: (2013)

Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
ανά: Krum, H, κ.ά.
Έκδοση: (2010)

Metabolic syndrome and alanine aminotransferase: a global perspective from the NAVIGATOR screening population.
ανά: Bethel, M, κ.ά.
Έκδοση: (2009)

Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
ανά: Califf, R, κ.ά.
Έκδοση: (2008)

Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for hypertension on clinical end points: a cohort study.
ανά: McMurray, J, κ.ά.
Έκδοση: (2012)

Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Hypertension on Clinical End Points: A Cohort Study
ανά: Mcmurray, J, κ.ά.
Έκδοση: (2012)

Change in levels of physical activity after diagnosis of type 2 diabetes: an observational analysis from the NAVIGATOR study.
ανά: Preiss, D, κ.ά.
Έκδοση: (2014)

Cardiologists should care about glucose: most people with CV disease or risk factors have diabetes or significant glycaemic abnormalities. Results of screening over 39,000 subjects for NAVIGATOR
ανά: McMurray, J, κ.ά.
Έκδοση: (2004)

Prediabetes and the risk of diabetes.
ανά: McMurray, J, κ.ά.
Έκδοση: (2012)

Change in levels of physical activity after diagnosis of type 2 diabetes: An observational analysis from the NAVIGATOR study
ανά: Preiss, D, κ.ά.
Έκδοση: (2014)

Determining the most appropriate components for a composite clinical trial outcome.
ανά: Bethel, M, κ.ά.
Έκδοση: (2008)

Frequency of abnormal glucose tolerance and the metabolic syndrome in people at increased cardiovascular disease risk screened for the NAVIGATOR trial
ανά: Holman, R, κ.ά.
Έκδοση: (2003)

Chronic obstructive pulmonary disease and cardiovascular risk: insights from the NAVIGATOR trial.
ανά: de Barros e Silva, P, κ.ά.
Έκδοση: (2014)

Effect of valsartan on kidney outcomes in people with impaired glucose tolerance.
ανά: Currie, G, κ.ά.
Έκδοση: (2017)

Risk factors for fatal and non-fatal cardiovascular events in 9306 subjects in the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial
ανά: Mcmurray, J, κ.ά.
Έκδοση: (2011)

Do Diuretics, Beta-Blockers, and Statins Increase the Risk of Diabetes in Patients with Impaired Glucose Tolerance? Insights from the NAVIGATOR Study
ανά: Shen, L, κ.ά.
Έκδοση: (2012)

Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
ανά: Latini, R, κ.ά.
Έκδοση: (2013)

Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
ανά: Preiss, D, κ.ά.
Έκδοση: (2012)

Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.
ανά: Shen, L, κ.ά.
Έκδοση: (2013)

Rationale and design of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
ανά: Bethel, M, κ.ά.
Έκδοση: (2009)

A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk
ανά: Bethel, M, κ.ά.
Έκδοση: (2013)

A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk.
ανά: Bethel, M, κ.ά.
Έκδοση: (2013)

People at increased risk of cardiovascular disease screened for the NAVIGATOR trial frequently have undiagnosed diabetes or impaired glucose tolerance
ανά: Califf, R, κ.ά.
Έκδοση: (2003)

Anthocyanins in chokeberry and purple maize attenuate diet-induced metabolic syndrome in rats
ανά: Bhaswant, Maharshi, κ.ά.
Έκδοση: (2017)

The cost of the metabolic syndrome in the elderly: Findings from the cardiovascular health study
ανά: Curtis, L, κ.ά.
Έκδοση: (2007)

Stubborn: A Strong Baseline for the Indoor Object Navigation Task
ανά: Luo, Haokuan
Έκδοση: (2022)

Hippurate as a metabolomic marker of gut microbiome diversity: Modulation by diet and relationship to metabolic syndrome
ανά: Pallister, T, κ.ά.
Έκδοση: (2017)

Costs of the metabolic syndrome in elderly individuals: findings from the Cardiovascular Health Study.
ανά: Curtis, L, κ.ά.
Έκδοση: (2007)

Metabolic syndrome in polycystic ovary syndrome.
ανά: Barber, T, κ.ά.
Έκδοση: (2007)

Role of lifestyle and oral anti-diabetic agents to prevent type 2 diabetes mellitus and cardiovascular disease.
ανά: Bethel, M, κ.ά.
Έκδοση: (2007)

Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
ανά: Preiss, D, κ.ά.
Έκδοση: (2013)

Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes.
ανά: Kahn, SE, κ.ά.
Έκδοση: (2006)

Fat metabolism and the metabolic syndrome
ανά: Bickerton, A, κ.ά.
Έκδοση: (2008)

International variation in outcomes among people with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the NAVIGATOR Trial.
ανά: Dos Santos, M, κ.ά.
Έκδοση: (2017)